Atria Investments Inc Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN

Atria Investments Inc boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,469 shares of the biopharmaceutical company’s stock after purchasing an additional 1,442 shares during the period. Atria Investments Inc’s holdings in Regeneron Pharmaceuticals were worth $6,021,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of REGN. Activest Wealth Management increased its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Finally, Colonial Trust Advisors purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.3%

NASDAQ REGN opened at $651.80 on Friday. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $883.15. The firm has a market capitalization of $69.08 billion, a PE ratio of 15.61, a P/E/G ratio of 2.03 and a beta of 0.31. The stock’s 50 day moving average is $581.80 and its 200 day moving average is $565.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the previous year, the company posted $12.46 earnings per share. The company’s revenue for the quarter was up .9% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on REGN. Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research note on Monday, August 4th. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Finally, Cantor Fitzgerald lifted their price target on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $802.36.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.